Sunshine Biopharma
SBFM • NASDAQ
Sunshine Biopharma is a drug manufacturers - specialty & generic company in the healthcare sector trading on NASDAQ, led by CEO Steve N. Slilaty, with a market cap of $5.6M.
CEOSteve N. Slilaty
Market Cap$5.6M
Drug Manufacturers - Specialty & Generic
Healthcare
Employees44.0
Websitesunshinebiopharma.com
Country
United States of America
Next Earnings
Upcoming earnings announcement for Sunshine Biopharma
Date
Tuesday, March 31, 2026 (in 2 months)
Timing
After Market Close (5:00 PM New York)
Fiscal Period
Q4 2025
EPS Estimate
-$0.27
Revenue Estimate
$10.0M
Earnings History
Past 12 earnings reports for Sunshine Biopharma
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2025 | Q3 2025 | -$0.19Est: -$0.12 | -58.3% | $9.4MEst: $12.0M | -21.5% |  10-Q |
| Aug 12, 2025 | Q2 2025 | -$0.39 | — | $9.4MEst: $12.1M | -22.2% | 10-Q |
| May 15, 2025 | Q1 2025 | -$0.44 | — | $8.9M | — | 10-Q |
| Apr 1, 2025 | Q4 2024 | -$1.00 | — | $9.6MEst: $12.5M | -23.2% | — |
| Nov 5, 2024 | Q3 2024 | -$0.94Est: $0.00 | — | $8.4MEst: $11.8M | -28.5% | 10-Q |
| Aug 16, 2024 | Q2 2024 | -$9.94Est: -$7.40 | -34.3% | $9.3MEst: $9.0M | +3.4% | 10-Q/A |
| May 20, 2024 | Q1 2024 | -$40.00Est: -$160.00 | +75.0% | $7.5MEst: $7.0M | +7.7% | 10-Q |
| Mar 28, 2024 | Q4 2023 | -$120.00Est: -$60.00 | -100.0% | $7.7MEst: $6.1M | +25.9% | 10-K |
| Nov 13, 2023 | Q3 2023 | -$80.00Est: -$120.00 | +33.3% | $5.6MEst: $6.0M | -6.7% | — |
| Aug 10, 2023 | Q2 2023 | -$40.00 | — | $5.6M | — | 10-Q |
| May 10, 2023 | Q1 2023 | -$160.00 | — | $4.9M | — | 10-Q |
| Apr 4, 2023 | Q4 2022 | -$3,000.00 | — | $3.9M | — | — |